Pathologic assessment of vasculopathies in pulmonary hypertension.
By G. Pietra, F. Capron, S. Stewart, O. Leone, M. Humbert, I. Robbins, L. Reid, R. Tuder. Journal of the American College of Cardiology, 2004
704 citations recorded by the source corpus.
Subfields: Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/88dff30c97044416b9ee64a0a01284eb03781277
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- IL-6 Overexpression Induces Pulmonary Hypertension (2008, positive): “remodeling in Tg mice is similar to that seen in patients with severe PAH,5 with (1) concentric intimal wall thickening, (2)”
- Tadalafil Therapy for Pulmonary Arterial Hypertension (2009, neutral): “Epistaxis 3 (4) 6 (7) 4 (5) 5 (6) 3 (4)”
- Pulmonary arterial hypertension (2013, background): “ous vascular compartments: focal intimal thickening of small pulmonary arteries, preferably beyond branching points and exuberant endothelial cell proliferation, leading to the formation of capillary-like, sinusoidal channels on a smooth muscle cell and collagen-rich matrix within the native arteria”
- Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society (2015, background): “The histopathologic hallmark of PVOD is widespread fibrous intimal proliferation that involves predominantly pulmonary venules and small veins, whereas IPAH is characterized by frequent plexiform and possible thrombotic lesions.(384,385) Histological proof is generally required to make the diagnosis”